Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A CGRP receptor antagonist peptide formulated for nasal administration to treat migraine

Journal of Pharmacy and Pharmacology(2020)10.1111/jphp.13317Source: DataRank Database

A CGRP receptor antagonist peptide formulated for nasal administration to treat migraine is a research paper published in Journal of Pharmacy and Pharmacology (2020). On theSindex it has a DataRank of 0. It has been cited 14 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access14 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 1.56)OA: hybridTopics (61)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Andrew F. Russo ORCID,Zhongming Zhang ORCID,Adisa Kuburas ORCID,Patrick M. Killoran ORCID,Vera D’Aloisio ORCID

Live enrichment

PubMed:32588458 OpenAlex:https://openalex.org/W3038032073

Foundation for the National Institutes of Health

Grant: NS075599

Innovate UK

Grant: 132677

Development of small peptide CGRP antagonists for migraine therapy

National Institutes of Health

Grant: 5R01NS075599-02

CGRP-induced light aversion in a preclinical migraine model

FWCI

1.56

Citation Percentile

0.8%

Citation Trend

2021

2022

2023

2024

2025

hybridLicense: cc-by-nc

journalhttps://academic.oup.com/jpp/article-pdf/72/10/1352/36588895/jphp13317.pdf

publisherhttps://academic.oup.com/jpp/article-pdf/72/10/1352/36588895/jphp13317.pdf

publisherhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fjphp.13317

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/jphp.13317

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1111/jphp.13317

Fields of Study

Migraine and Headache StudiesAdvanced Drug Delivery SystemsNeuropeptides and Animal Physiology0301 basic medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

Calcitonin Gene-Related Peptide Receptor AntagonistsAdministration, IntranasalAnimalsCricetulusDose-Response Relationship, DrugDrug CompoundingCricetinaeMice, Inbred C57BLMigraine DisordersCHO CellsReceptors, Calcitonin Gene-Related PeptideCell Line, TumorMice

Keywords

Calcitonin gene-related peptideAntagonistIn vivoChemistryPharmacologyReceptorPeptideReceptor antagonistExtravasationCalcitoninPotencyMigraineIn vitroMedicineEndocrinologyInternal medicineNeuropeptideBiochemistryImmunologyBiologyRMDrug CompoundingMigraine DisordersCHO CellsMiceCricetulusCalcitonin Gene-Related Peptide Receptor AntagonistscAMPCell Line, TumorCricetinaeaCGRP (8-37)AnimalsaCGRP (27-37)Administration, IntranasalDose-Response Relationship, Drugplasma extravasationRM Therapeutics. PharmacologySK-N-MCMice, Inbred C57BLaCGRP (8-37) ; aCGRP (27-37) ; cAMP ; plasma extravasation ; SK-N-MCResearch PaperReceptors, Calcitonin Gene-Related Peptide

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being